A few weeks before the announcement, Vaxart granted amendments to the warrants agreements, which allowed Armistice to sell almost all of their stock, which they did once the stock price skyrocketed.
Vaxart has not been chosen by Operation Warp Speed to receive research funding, but instead had limited involvement, HHS told the New York Times in July. Vaxart’s vaccine, an oral tablet, was only involved in preliminary studies on primates sponsored by Warp Speed.
In a statement to CNN Business Saturday, the company said, “The Vaxart non-human primate challenge study was organized and funded by Operation Warp Speed, as stated in the June 26, 2020 company press release. The statements made in that press release are accurate and any allegation to the contrary is baseless.”
In its October SEC filing, Vaxart wrote that it has provided documents called for by the subpoena to demonstrate its role in Operation Warp Speed. “The company has voluntarily provided documents requested by the SEC and is cooperating with this informal inquiry,” it stated.
On October 14, Vaxart announced encouraging results from its study on hamsters that received oral dosages of its Covid-19 vaccine.
The stock was down 3.5%, to approximately $6, as of Friday evening.